Resetting the Immune System to Drive Long-Term Disease Remission in Autoimmune and Allergic Diseases with Jonathan Rigby Revolo Biotherapeutics TRANSCRIPT
Download PDFApr 6, 2021
Jonathan Rigby, CEO, Revolo Biotherapeutics discusses the company's revolutionary therapies powered to reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, with less frequent chronic dosing and without suppression of the immune system. A goal that others...
Apr 6, 2021
Jonathan Rigby, CEO, Revolo Biotherapeutics discusses the company's revolutionary therapies powered to reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, with less frequent chronic dosing and without suppression of the immune system. A goal that others...
Developing Immunotherapeutic Technologies to Combat Infectious Disease and Cancer With Dr. Tim Rodell Aethlon Medical TRANSCRIPT
Download PDFAug 31, 2020
Dr. Tim Rodell, Chief Executive Officer, Aethlon Medical brings us up to speed on the work at Aethlon in developing immunotherapeutic technologies using their Hemopurifier to clear a virus as well as exosomes in patients with cancer as blood flows through the nanofibers of the Hemopurifier cartridge. With more recent...
Aug 31, 2020
Dr. Tim Rodell, Chief Executive Officer, Aethlon Medical brings us up to speed on the work at Aethlon in developing immunotherapeutic technologies using their Hemopurifier to clear a virus as well as exosomes in patients with cancer as blood flows through the nanofibers of the Hemopurifier cartridge. With more recent...
Using Immunotherapy to Treat Glioblastoma Most Aggressive Brain Cancer with Dr. Apostolos Stathopoulos ERC Immunotherapy TRANSCRIPT
Download PDFAug 5, 2020
Apostolos Stathopoulos, CEO, ERC-Belgium talks about using immunotherapy to treat glioblastoma, the most malignant of all gliomas or brain cancers. ERC's therapy, which stimulates the patient's immune system to mount an immune response against the tumor cells, has demonstrated a clinically meaningful survival benefit...